DUSA Pharmaceuticals, Inc. (NASDAQ NMS:DUSA) reported today fourth quarter and full year 2005 financial results and corporate highlights. During the fourth quarter and full year, the Company's revenues from product sales were $3,348,000 and $11,337,000 respectively, compared to $2,545,000 and $7,988,000 respectively in the comparable 2004 periods, reflecting record Kerastick(R) sales of the Company's Levulan(R) photodynamic therapy in dermatology.
